Stock in Focus: CareFusion Corporation (NYSE:CFN)

[Zacks] CareFusion Corporation (NYSE:CFN) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because CFN is now in overbought territory with an RSI value of 83.32.Stock PerformanceTaking a look at the company’s recent performance, CareFusion Corporation (CFN) reported fourth quarter earnings for fiscal 2014 on July 08^th. The company reported actual earnings per share of $0.79 against the consensus Street estimate of $0.72. This represents year over year growth of 22.20%. CareFusion posted revenue of $1.12 billion against estimates of $1.04 billion.CareFusion Corporation (CFN) is currently valued at $11.49 billion and closed the last trading session at $56.64. The stock has a 50-day moving average of $45.78 and a 200-day moving average of $43.05.

Is this a Buying Opportunity?There are currently seven analysts that we track that cover the stock. Of those seven, two have a Buy rating, one has strongly Buy and four have a hold rating. On a consensus basis this yields a score of 2.57 and a Buy. The combined price objective of these covering analysts is $45.54, which represents a 1.36% downside difference to the last closing price.The most recent analyst activity consisted of Bank of America reiterating rating with Buy stance on the company. Bank of America has a price target of $50 which represents an upside of 11.98% from the last closing price. On the date of the report, the stock closed at $44.65Another research firm weighing in recently was Raymond James who also reiterated their rating on the stock. On August 15^th Raymond James boosted their price target on the stock from $ 50.00 to 52.00 or a 13.71% upside to the current price. On the day of the report, CFN shares closed at $43.97.Company ProfileCareFusion (NYSE:CFN), a medical technology company, provides various healthcare products and services. It offers product lines in the areas of medication management, infection prevention, operating room effectiveness, and respiratory care. The company operates through two segments, Medical Systems and Procedural Solutions. Its primary product brands include Alaris intravenous (IV) infusion systems; Pyxis and Rowa automated medication dispensing and supply management systems; AVEA, Vela, and LTV Series respiratory ventilators etc.